Nom du produit:oxan-4-ol

IUPAC Name:oxan-4-ol

CAS:2081-44-9
Formule moléculaire:C5H10O2
Pureté:95%+
Numéro de catalogue:CM103849
Poids moléculaire:102.13

Unité d'emballage Stock disponible Prix($) Quantité
CM103849-100g in stock ȋş
CM103849-500g in stock ƅƅǺ

Pour une utilisation en R&D uniquement..

Formulaire de demande

   refresh    

Détails du produit

N° CAS:2081-44-9
Formule moléculaire:C5H10O2
Point de fusion:-
Code SMILES:OC1CCOCC1
Densité:
Numéro de catalogue:CM103849
Poids moléculaire:102.13
Point d'ébullition:183°C at 760 mmHg
N° Mdl:MFCD00006633
Stockage:Store at 2-8°C.

Category Infos

Tetrahydropyrans
Tetrahydropyran is an organic compound consisting of a saturated six-membered ring containing five carbon atoms and one oxygen atom. Tetrahydropyrans are common structural motifs in natural products and synthetic therapeutic molecules. In nature, these six-membered oxygen heterocycles are usually assembled by intramolecular reactions, including oxygen Michael addition or ring opening of epoxy alcohols. In fact, polyether natural products have been particularly extensively studied for their fascinating structures and important biological properties; these are often formed through endoselective epoxy open cascades.

Column Infos

Pyrans
Pyrans are an important class of six-membered heterocyclic compounds, non-aromatic rings, composed of five carbon atoms and one oxygen atom, and contain two double bonds. The molecular formula of pyran is C5H6O, and there are two isomers. Pyrans, together with benzo derivatives, form scaffolds for a variety of drug applications, many of which are approved and promising candidates in clinical trials and recently isolated bioactive natural products.
SE-9
SE-9 is a novel dual-targeting SOS1/EGFR inhibitor that represents a promising treatment strategy for prostate cancer.
Multitarget medications represent an appealing therapy against the disease with multifactorial abnormalities─cancer. Therefore, simultaneously targeting son of sevenless 1 (SOS1) and epidermal growth factor receptor (EGFR), two aberrantly expressed proteins crucial for the oncogenesis and progression of prostate cancer, may achieve active antitumor effects.